Management and nursing strategies for different patterns of adverse events in patients with urological cancer treated with immune checkpoint inhibitors
作者机构：Department of UrologyPeking University Third HospitalBejingChina
出 版 物：《Current Urology》 (当代泌尿学（英文）)
年 卷 期：2024年第18卷第3期
页 面：212-217页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Immune checkpoint inhibitor Immunotherapy Adverse events Nursing Urological tumor
摘 要：Background This study aimed to explore the patterns of treatment-related adverse events(AEs)associated with immune checkpoint inhibitor(ICI)monotherapy and in combination with chemotherapy or tyrosine kinase inhibitor(TKI)therapy and to summarize the corresponding management and nursing *** and methods A total of 69 patients with malignant urological tumors who received ICI treatment between June 2019 and October 2022 were retrospectively analyzed,and AEs that occurred during treatment were observed and *** on the different types of treatment,the patients were divided into ICI monotherapy,ICI plus chemotherapy,and ICI plus TKI therapy *** analysis was *** incidence,distribution,and severity of AEs in the different subgroups were *** A total of 138 AEs occurred in 69 patients,among which grade 1 plus 2,and grade 3 plus 4 AEs accounted for 78.99%and 21.01%,*** incidence of AEs per patient in the ICI-TKI therapy group was the highest(3.75 times/person),followed by the ICI-chemotherapy(2.33 times/person)and ICI monotherapy(0.82 times/person)*** AEs,such as fatigue,nausea,and myelosuppression,were much more common in the ICI-gemcitabine and cisplatin group,whereas renal injury,skin lesions,and diarrhea were most common ones in the ICI-TKI *** Immune checkpoint inhibitors are new treatment options for advanced urological tumors and renal cell *** AE patterns were observed among the different treatment ***,strict and meticulous clinical management and nursing measures are required to ensure the safety of patients receiving ICI treatment.
维普期刊数据库